These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38146985)

  • 1. SARS-CoV-2 Incubation Period during Omicron BA.5-Dominant Period, Japan.
    Cheng HY; Akhmetzhanov AR; Dushoff J
    Emerg Infect Dis; 2024 Jan; 30(1):206-207. PubMed ID: 38146985
    [No Abstract]   [Full Text] [Related]  

  • 2. SARS-CoV-2 Incubation Period during Omicron BA.5-Dominant Period, Japan (Response).
    Ogata T; Tanaka H
    Emerg Infect Dis; 2024 Jan; 30(1):207. PubMed ID: 38146992
    [No Abstract]   [Full Text] [Related]  

  • 3. SARS-CoV-2 Incubation Period during the Omicron BA.5-Dominant Period in Japan.
    Ogata T; Tanaka H
    Emerg Infect Dis; 2023 Mar; 29(3):595-598. PubMed ID: 36787734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serial Intervals and Incubation Periods of SARS-CoV-2 Omicron and Delta Variants, Singapore.
    Zeng K; Santhya S; Soong A; Malhotra N; Pushparajah D; Thoon KC; Yeo B; Ho ZJM; Cheng MCI
    Emerg Infect Dis; 2023 Apr; 29(4):814-817. PubMed ID: 36878009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coronavirus Disease 19 (COVID-19) Vaccine Effectiveness Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study (Factors Associated with SARS-CoV-2 Infection and the Effectiveness of COVID-19 Vaccines Study).
    Arashiro T; Arima Y; Muraoka H; Sato A; Oba K; Uehara Y; Arioka H; Yanai H; Kuramochi J; Ihara G; Chubachi K; Yanagisawa N; Nagura Y; Kato Y; Ueda A; Numata A; Kato H; Ishii K; Ooki T; Oka H; Nishida Y; Stucky A; Smith C; Hibberd M; Ariyoshi K; Suzuki M
    Clin Infect Dis; 2023 Feb; 76(3):e108-e115. PubMed ID: 35918782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary Attack Rate, Transmission and Incubation Periods, and Serial Interval of SARS-CoV-2 Omicron Variant, Spain.
    Del Águila-Mejía J; Wallmann R; Calvo-Montes J; Rodríguez-Lozano J; Valle-Madrazo T; Aginagalde-Llorente A
    Emerg Infect Dis; 2022 Jun; 28(6):1224-1228. PubMed ID: 35393009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiology of SARS-CoV-2 Omicron BA.5 Infections, Macau, June-July 2022.
    Xiong W; Peng L; Tsang TK; Cowling BJ
    Emerg Infect Dis; 2023 Feb; 29(2):453-456. PubMed ID: 36648122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum Neutralization of SARS-CoV-2 Omicron BA.1 and BA.2 after BNT162b2 Booster Vaccination.
    Pedersen RM; Bang LL; Madsen LW; Sydenham TV; Johansen IS; Jensen TG; Justesen US; Andersen TE
    Emerg Infect Dis; 2022 Jun; 28(6):1274-1275. PubMed ID: 35356875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omicron BA.5 Neutralization among Vaccine-Boosted Persons with Prior Omicron BA.1/BA.2 Infections.
    Pedersen RM; Bang LL; Tornby DS; Madsen LW; Holm DK; Sydenham TV; Johansen IS; Jensen TG; Justesen US; Andersen TE
    Emerg Infect Dis; 2022 Dec; 28(12):2575-2577. PubMed ID: 36347270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reinfections with Different SARS-CoV-2 Omicron Subvariants, France.
    Nguyen NN; Houhamdi L; Delorme L; Colson P; Gautret P
    Emerg Infect Dis; 2022 Nov; 28(11):2341-2343. PubMed ID: 36150518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of and Risk Factors for Post-COVID-19 Condition during Omicron BA.5-Dominant Wave, Japan.
    Iba A; Hosozawa M; Hori M; Muto Y; Muraki I; Masuda R; Tamiya N; Iso H
    Emerg Infect Dis; 2024 Jul; 30(7):1380-1389. PubMed ID: 38916571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Shorter Incubation Period among COVID-19 Cases with the BA.1 Omicron Variant.
    Tanaka H; Ogata T; Shibata T; Nagai H; Takahashi Y; Kinoshita M; Matsubayashi K; Hattori S; Taniguchi C
    Int J Environ Res Public Health; 2022 May; 19(10):. PubMed ID: 35627870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 Variants and Age-Dependent Infection Rates among Household and Nonhousehold Contacts.
    Miyahara R; Tamura K; Kato T; Nakazaki M; Otani K; Ko YK; Kamigaki T; Arima Y; Tani H; Oishi K; Suzuki M
    Emerg Infect Dis; 2023 Aug; 29(8):1648-1650. PubMed ID: 37343546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Duration of Infectious Virus Shedding by SARS-CoV-2 Omicron Variant-Infected Vaccinees.
    Takahashi K; Ishikane M; Ujiie M; Iwamoto N; Okumura N; Sato T; Nagashima M; Moriya A; Suzuki M; Hojo M; Kanno T; Saito S; Miyamoto S; Ainai A; Tobiume M; Arashiro T; Fujimoto T; Saito T; Yamato M; Suzuki T; Ohmagari N
    Emerg Infect Dis; 2022 May; 28(5):998-1001. PubMed ID: 35290176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seroprevalence of Specific SARS-CoV-2 Antibodies during Omicron BA.5 Wave, Portugal, April-June 2022.
    Kislaya I; Melo A; Barreto M; Henriques C; Aniceto C; Manita C; Ramalhete S; Santos JA; Soeiro S; Rodrigues AP;
    Emerg Infect Dis; 2023 Feb; 29(3):590-594. PubMed ID: 36732078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Replacement dynamics and the pathogenesis of the Alpha, Delta and Omicron variants of SARS-CoV-2.
    Ward T; Glaser A; Overton CE; Carpenter B; Gent N; Seale AC
    Epidemiol Infect; 2022 Dec; 151():e32. PubMed ID: 36535802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. University-Associated SARS-CoV-2 Omicron BA.2 Infections, Maricopa County, Arizona, USA, 2022.
    Fowle N; Garrett B; Floyd OL; Collins J; Krasnow AD; Islas M; Holland SC; Smith MF; Lim ES; Jarrett NM; Scott SE
    Emerg Infect Dis; 2022 Jul; 28(7):1520-1522. PubMed ID: 35654405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergence and Persistent Dominance of SARS-CoV-2 Omicron BA.2.3.7 Variant, Taiwan.
    Shao PL; Tu HC; Gong YN; Shu HY; Kirby R; Hsu LY; Yeo HY; Kuo HY; Huang YC; Lin YF; Weng HY; Wu YL; Chen CC; Chen TW; Lee KM; Huang CG; Shih SR; Chen WJ; Wu CC; Yu CJ; Tsai SF
    Emerg Infect Dis; 2023 Apr; 29(4):792-796. PubMed ID: 36918378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology of Infections with SARS-CoV-2 Omicron BA.2 Variant, Hong Kong, January-March 2022.
    Mefsin YM; Chen D; Bond HS; Lin Y; Cheung JK; Wong JY; Ali ST; Lau EHY; Wu P; Leung GM; Cowling BJ
    Emerg Infect Dis; 2022 Sep; 28(9):1856-1858. PubMed ID: 35914518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2 Omicron BA.1 Challenge after Ancestral or Delta Infection in Mice.
    Baz M; Deshpande N; Mackenzie-Kludas C; Mordant F; Anderson D; Subbarao K
    Emerg Infect Dis; 2022 Nov; 28(11):2352-2355. PubMed ID: 36191630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.